Steve Jobs’s Pancreatic Cancer Was Rare Type


Published On: October 7th, 2011

Steve Jobs had what is called a neuroendocrine pancreatic tumor, a type that accounts for fewer than 5% of pancreatic cancers and, experts say, differs substantially from the more common kind. Ron Winslow has details on Lunch Break.

Go here to read the rest:
Steve Jobs’s Pancreatic Cancer Was Rare Type/a>

STOP PANIC ATTACKS - A Natural Technique To Stop Panic Attacks and Anxiety Fast!

Stop Panic Attacks
The technique I teach has been developed by me Joe Barry, a former sufferer of all too frequent panic attacks and GAD. I developed a completely natural approach to eliminating 100% of general anxiety and panic attacks. This may seem very hard to believe for someone who may have had this condition for some time but believe me the new information is now available to be free from anxiety. I will reveal the whole technique to you.

try-now

YouTube Video



Loading...


Did You Know Did you know:


Prostate: 155.4 per 100,000 men per year

Related Posts

  • Jobs’s Death Focuses Attention on Rare Form of Pancreatic Cancer
    Apple CEO Steve Jobs famously kept quiet about his illness and while a rare form of pancreatic cancer was at the root of his struggles, the company’s announcement of his death yesterday didn’t include information about the precise cause. But if you ever question what someone can accomplish after being diagnosed with cancer, consider this...
  • Farrah Fawcett’s Death Spotlights Rare Cancer Type
    Farrah Fawcett’s death today after a lengthy battle with anal cancer, which eventually spread to her liver, spotlights a rare type of the disease. Anal cancer will strike an estimated 5,300 Americans and cause 710 deaths in 2009, according to the National Cancer Institute ..
  • Reader Consult: Are These The Top 5 Ways To Improve Primary Care?
    What could primary-care physicians do differently to benefit patients’ health and cut risks, harms and costs? The National Physicians Alliance, a 22,000-member group of doctors that advocates for affordable, universal health care, came out with its own list — lists, actually, since there’s one each for family medicine, internal medicine and pediatrics. ..
  • A.M. Vitals: Novartis Won’t Develop Tasigna for Rare Stomach Cancer
    Ending Development: Novartis said it will no longer seek to develop its cancer drug Tasigna as a first-line treatment for a certain type of stomach cancer, the WSJ reports . The drug is unlikely to outperform the company’s Gleevec, now used to treat the disease, the paper says. Anticipating Bids ..
  • Out-of-Pocket Costs for Some Cancer Patients Top $700 Monthly
    The cost of cancer treatment is high and, according to the National Cancer Institute, growing . And at the individual level, the financial burden can be very heavy, even for patients with insurance. A new study from Duke University Medical Center and Dana-Farber Cancer Institute covers 216 cancer patients, mostly older females with breast cancer ..
  • A.M. Vitals: Cancer Drugs By Bristol and Novartis May Top Gleevec
    Also: what the Internet may be doing to your brain; Medicare Advantage rates for 2011; physician shortages ahead? ..
Leave a comment
Comments are closed.
« Jobs’s Death Focuses Attention on Rare Form of Pancreatic Cancer U.K. Pledges $31 Million to Help Wipe Out Guinea Worm Disease »